Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study

• DOI: 10.3389/fonc.2022.976078
• Publication Date: 2023-01-05T17:39:40Z
• Authors: Tao Li; Tingting Liu; Lei Zhao; Lu Liu; Xuan Zheng; Jinliang Wang; Fan Zhang; Yi Hu
• Keywords: Combination therapy; Progression-free survival

Purpose Gastric cancer (GC) is one of the most frequently diagnosed cancers and leading causes deaths worldwide, especially in eastern Asia China. Anti-PD-1 immune checkpoint inhibitors, Pembrolizumab Nivolumab, have been approved for treatment locally advanced or metastatic gastric gastroesophageal junction (GC/GEJC). Our study evaluated effectiveness safety anti-PD-1-based (monotherapy combination therapy) Chinese patients with GC/GEJCs a real-world setting. Methods A retrospective cohort was conducted, 54 from May 31, 2015, to 2021, were included our analysis, including 19 treated anti-PD-1 monotherapy 35 therapy. Demographic clinical information evaluated. Clinical response, survival outcomes, profile measured analyzed. Results Overall, median overall (mOS) 11.10 months (95% CI, 7.05–15.15), progression-free (mPFS) 3.93 2.47–5.39). Of patients, 16.7% achieved 72.2% disease control. Prolonged (OS) (PFS) increased response observed group compared group, although statistical significance not reached. In subgroups live metastases elevated baseline neutrophil-to-lymphocyte ratio (NLR) levels, therapy outperformed alone outcomes. Patients (n = 5, 26.3%) had fewer treatment-related adverse events (TRAEs) than those 22, 62.9%). There also TRAEs grades 3–5 2, 10.5%) 7, 20.0%). Pneumonitis three only potential immune-related event reported. Conclusions Anti-PD-1-based showed favorable outcomes manageable profiles GC/GEJCs. treatment, immunotherapy should be an indispensable choice strategy GC/GEJC. heavy tumor burden more sites might benefit Elderly lines high Eastern Cooperative Oncology Group (ECOG) performance scores suitable monotherapy, some benefits observed.